Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

被引:0
|
作者
Peeters, M.
Van Cutsem, E.
Berlin, J.
Hecht, J. R.
Ruiz, R.
Navale, L.
Amado, R.
Meropol, N. J.
机构
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
4138
引用
收藏
页数:2
相关论文
共 50 条
  • [21] Panitumumab and inhibition of the epidermal growth factor receptor signaling in the treatment of metastatic colorectal cancer
    Wyrwicz, Lucjan S.
    Nowecki, Zbigniew I.
    ONCOLOGY IN CLINICAL PRACTICE, 2010, 6 (06): : 290 - 300
  • [22] Treatment and outcomes of patients with metastatic colorectal cancer (mCRC) with epidermal growth factor receptor (EGFR) therapy in the third-line setting
    Ho, Maria Yi
    Renouf, Daniel John
    Cheung, Winson Y.
    Zhou, Chen
    Goktepe, Ozge
    Lim, Howard John
    Kennecke, Hagen F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [23] Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
    Tougeron D.
    Cortes U.
    Ferru A.
    Villalva C.
    Silvain C.
    Tourani J.M.
    Levillain P.
    Karayan-Tapon L.
    Cancer Chemotherapy and Pharmacology, 2013, 72 (2) : 397 - 403
  • [24] Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
    Sartore-Bianchi, Andrea
    Moroni, Mauro
    Veronese, Silvio
    Carnaghi, Carlo
    Bajetta, Emilio
    Luppi, Gabriele
    Sobrero, Alberto
    Barone, Carlo
    Cascinu, Stefano
    Colucci, Giuseppe
    Cortesi, Enrico
    Nichelatti, Michele
    Gambacorta, Marcello
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) : 3238 - 3245
  • [25] Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
    Jeong, Woo-Jeong
    Cha, Pu-Hyeon
    Choi, Kang-Yell
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9862 - 9871
  • [26] Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
    Woo-Jeong Jeong
    Pu-Hyeon Cha
    Kang-Yell Choi
    World Journal of Gastroenterology, 2014, (29) : 9862 - 9871
  • [27] Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
    Rowinsky, EK
    Schwartz, GH
    Gollob, JA
    Thompson, JA
    Vogelzang, NJ
    Figlin, R
    Bukowski, R
    Haas, N
    Lockbaum, P
    Li, YP
    Arends, R
    Foon, KA
    Schwab, G
    Dutcher, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3003 - 3015
  • [28] Responsiveness to panitumumab (ABX-EGF), a fully human monoclonal antibody to epidermal growth factor receptor, in human breast carcinoma xenografts
    Bush, T
    Baher, A
    McDorman, K
    Ogbagabriel, S
    Freeman, D
    Radinsky, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S131 - S131
  • [29] Safety and efficacy of panitumumab monotherapy in the treatment of metastatic colorectal cancer (MCRC) - Summary of results across clinical studies
    Berlin, Jordan
    Van Cutsem, Eric
    Peeters, Marc
    Hecht, J. Randolph
    Wolf, Michael
    Amado, Rafael
    Meropol, Neal J.
    ANNALS OF ONCOLOGY, 2006, 17 : 114 - 115
  • [30] First line therapy of Panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC)
    Berlin, J.
    Posey, J.
    Tchekmedyian, S.
    Hu, E.
    Chan, D.
    Malik, I.
    Yang, L.
    MacDonald, M.
    Jerian, S.
    Hecht, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 185 - 185